CN102048895B - Pure traditional Chinese medicine preparation for treating dilated cardiomyopathy - Google Patents
Pure traditional Chinese medicine preparation for treating dilated cardiomyopathy Download PDFInfo
- Publication number
- CN102048895B CN102048895B CN2011100085877A CN201110008587A CN102048895B CN 102048895 B CN102048895 B CN 102048895B CN 2011100085877 A CN2011100085877 A CN 2011100085877A CN 201110008587 A CN201110008587 A CN 201110008587A CN 102048895 B CN102048895 B CN 102048895B
- Authority
- CN
- China
- Prior art keywords
- dilated cardiomyopathy
- radix
- treatment
- traditional chinese
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a pure traditional Chinese medicine preparation for treating dilated cardiomyopathy, which is prepared from astragali, radix salviae miltiorrhizae, red peony root, root-bark of peony, radix rehmanniae and the like as raw materials by steps of decocting twice, decocting filtrate, concentrating, granulating and packing in composite membrane bags. Shown by pharmacodynamic experiments of animals and clinical statistical results of patients, the pure traditional Chinese medicine preparation for treating dilated cardiomyopathy has the efficacies of supplementing qi, activating blood circulation, detoxifying and tranquilizing mind, and can eliminate the symptoms of chest distress, short breath, palpitation, edema, vexation, dark red tongue, yellow fur of tongue, thready rapid pulse, intermittent pulse and the like caused by deficiency of qi, blood stasis, toxic heat and heart disturbance due to dilated cardiomyopathy. The pure traditional Chinese medicine preparation can effectively resist myocardial fibrosis, improves the anoxia tolerance ability of myocardial cells and can be safely taken for a long time without toxic or side effect, the total effective rate in treating the dilated cardiomyopathy is 96.6%, and the curative effect is obviously better than that of conventional simple treatment of Western medicine.
Description
Technical field
The present invention relates to a kind of medicine of treating dilated cardiomyopathy, particularly treat the pure Chinese medicinal preparation of dilated cardiomyopathy.
Background technology
Dilated cardiomyopathy is a kind of agnogenic heart disease; Expanding and go down with contractile function with left chamber is characteristic; Its pathogenesis is not clear fully as yet; Except that spy's property sent out, Inheritance property, think that in recent years persistent virus infections are its important reasons, persistent virus infections comprise that to damage, the autoimmune of cardiac muscular tissue cell, autoantibody or cytokine mediated myocardial damage etc. can cause or bring out dilated cardiomyopathy.The clinical manifestation of disease later stage is heart failure and arrhythmia, and should disease prime of life sickness rate higher, does not still have the specific treatment method, though Western medicine makes significant progress for the treatment of heart failure at present, the survival rate in 5 years also has only 70%.At present, though the medicine of treatment dilated cardiomyopathy has certain curative effect, be prone to outbreak repeatedly after the drug withdrawal.
New through looking into; Study on prevention focus for dilated cardiomyopathy mainly concentrates on stem cell transplantation both at home and abroad; Gene-correlation property and relevant hyperfunction endocrine humoral factor inhibitor etc.; Because of having many technology and ethical issues, these researchs at present are confined to experimental stage more, also have with a certain distance from large-scale clinical practice.
Domestic and foreign literature is not found with the present invention and is formed identical report, and wherein Radix Rehmanniae, Radix Paeoniae Rubra, Cortex Moutan, Rhizoma Coptidis, Carapax Trionycis, Fructus Forsythiae, Radix Sophorae Flavescentis are not seen use in pertinent literature.
At present, do not find the similar products of treatment dilated cardiomyopathy, heart failure on the market.
Summary of the invention
The present invention aims to provide a kind of pure Chinese medicinal preparation that can effectively treat dilated cardiomyopathy, heart failure, to overcome the defective that prior art exists.
For realizing that the object of the invention realizes that through following measure pharmaceutical composition of the present invention is formulated by the crude drug of following ratio of quality and the number of copies:
The Radix Astragali 150～200; Radix Salviae Miltiorrhizae 90～150; Radix Paeoniae Rubra 50～80; Cortex Moutan 50～80;
Radix Rehmanniae 90～120; Carapax Trionycis 50～80; Fructus Forsythiae 50～90; Rhizoma Coptidis 18～30;
Radix Sophorae Flavescentis 50～80; Radix Glycyrrhizae 40～50.
Through decoct, concentrate, mixing, granulation, packing promptly get this preparation.
Above-mentioned each constituent mass portion rate can be adopted as:
The Radix Astragali 180; Radix Salviae Miltiorrhizae 120; Radix Paeoniae Rubra 60; Cortex Moutan 60; Radix Rehmanniae 120;
Carapax Trionycis 60; Fructus Forsythiae 80; Rhizoma Coptidis 24; Radix Sophorae Flavescentis 60; Radix Glycyrrhizae 40.
Through decoct, concentrate, mixing, granulation, packing promptly get this preparation.
The pure Chinese medicinal preparation of above-mentioned treatment dilated cardiomyopathy can adopt the method for preparing of following steps:
A, decoction: the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Cortex Moutan, Radix Rehmanniae, Carapax Trionycis, Fructus Forsythiae, Rhizoma Coptidis, Radix Sophorae Flavescentis, Radix Glycyrrhizae are added 7 times of water gagings decoct secondary, each 1.5 hours.
B, concentrated: above-mentioned decocting liquid is merged the back filter, filtrating is concentrated into the clear paste that relative density is 1.25-1.30 (60 ℃ of hot survey).
C, mixing:, regulate ointment, Icing Sugar and dextrin amount in the 1:3:1 ratio according to every batch of thick paste amount.
D, granulation: with Icing Sugar, dextrin mix homogeneously, make binding agent system soft material with thick paste, 14 eye mesh screens are granulated, 60-65 ℃ of oven dry, 10 eye mesh screen granulate.
E, packing: the dress compound membrane bag promptly gets this preparation.
The traditional Chinese medical science is thought the generation and the natural endowment idiosyncrasy of dilated cardiomyopathy; Factors such as the improper and warm repeatedly poison heresy of taking good care of oneself day after tomorrow invasion and attack are relevant; Positive QI-insufficiency, pyretic toxicity are invaded the key that the heart is the primary disease morbidity, this viewpoint and modern medicine this sick cause of disease understanding is not worked for and and.The sick position of primary disease is at the heart, and can involve internal organs such as lung, spleen, kidney, is basis with positive QI-insufficiency; Pyretic toxicity, blood stasis, water is wet, phlegm retention is a mark, is in a bad way and then develops into sudden depletion of heart-YANG; Negative and positive are died suddenly from cutting off, and belong to categories such as the traditional Chinese medical science " edema with the heart involved ", " cardiopalmus ", " thoracic obstruction ".
Based on the understanding of above Chinese and western medicine to the dilated cardiomyopathy etiology and pathogenesis, we bring into play the advantage of motherland's medical science, and " benefiting QI for activating blood circulation, detoxifcation mind calming " as fundamentals, developed the pure Chinese medicinal preparation of treatment dilated cardiomyopathy, heart failure.
Its pharmacology is: the Radix Astragali has the effect of QI invigorating and body resistance strengthening, diuretic detumescent, and Main Ingredients and Appearance is triterpene, flavonoid glycoside, polysaccharide, aminoacid and trace element, has effects such as enhancing human body immunity function, heart tonifying diuresis, fibrosis; Radix Salviae Miltiorrhizae has stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, and the effect of the relieving restlessness that clears away heart-fire, main chemical compositions are fat-soluble diterpene quinones and water solublity salvianolic acid class, wherein the water solublity salvianolic acid has the heart tonifying coronary dilating, promotes the reparation and the regeneration of cardiac muscular tissue; Radix Paeoniae Rubra has clearing away heat and cooling blood, the effect of eliminating stasis to stop pain; Cortex Moutan has clearing away heat and cooling blood, the effect of blood circulation promoting and blood stasis dispelling; Radix Rehmanniae has Yin-nourishing and body fluid promoting, the heat clearing away of invigorating blood circulation, and the effect except that arthralgia due to stagnation of blood mainly contains iridoid glycosides and polysaccharide composition, and pharmacological research shows to have obvious heart tonifying, increases the effect of rich output of heart and arteria coronaria flow; Carapax Trionycis has nourishing YIN for suppressing the hyperactive YANG, and the clots absorbing eliminating stagnation is brought down a fever and removed the effect of steaming, and mainly contains ossein, keratin, polysaccharide and various trace elements; Fructus Forsythiae has the effect of dispersing swelling and dissipating binds, heat-clearing and toxic substances removing, mainly contains compositions such as volatile oil, lignanoid, phenethyl alcohol glycoside.According to bibliographical information, Fructus Forsythiae water logging agent and ethanol extraction all have wider resisting pathogenic microbes, and gram positive bacteria, negative bacterium are all had very strong inhibitory action and strengthening heart and boosting pressure, microcirculation improvement effect; Rhizoma Coptidis has heat clearing and damp drying; The effect of eliminating fire and detoxication; Main effective ingredient is alkaloid (multiple alkaloids such as berberine, jateorhizine, palmatine, coptisine, 13-methyl-.psi.-coptisine .); Modern pharmacological research shows that berberine has resisting pathogenic microbes, resisting myocardial ischemia, arrhythmia, adjusting immunologic function, effects such as anticoagulant; Radix Sophorae Flavescentis has heat clearing and damp drying, parasite killing diuretic effect; Radix Glycyrrhizae has invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, the effect of coordinating the actions of various ingredients in a prescription.
The present invention is by Qi-tonifying drug, and blood circulation promoting and blood stasis dispelling and heat and toxic materials clearing away medicine compatibility form.The traditional Chinese medical science thinks that dilated cardiomyopathy takes place and the natural endowment idiosyncrasy; Factors such as the improper and warm repeatedly poison heresy of taking good care of oneself day after tomorrow invasion and attack are relevant; Positive QI-insufficiency, pyretic toxicity are invaded the key that the heart is the primary disease morbidity, this viewpoint and modern medicine this sick cause of disease understanding is not worked for and and.The sick position of primary disease is at the heart, and can involve internal organs such as lung, spleen, kidney, is basis with positive QI-insufficiency; Pyretic toxicity, blood stasis, water is wet, phlegm retention is a mark, is in a bad way and then develops into sudden depletion of heart-YANG; Negative and positive are died suddenly from cutting off, and belong to categories such as the traditional Chinese medical science " edema with the heart involved ", " cardiopalmus ", " thoracic obstruction ".Based on the understanding of above Chinese and western medicine to the dilated cardiomyopathy etiology and pathogenesis; To " benefiting QI for activating blood circulation; detoxifcation mind calming " as fundamentals; With the Radix Astragali, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Cortex Moutan, Radix Rehmanniae, Carapax Trionycis, Fructus Forsythiae, Rhizoma Coptidis, Radix Sophorae Flavescentis, Radix Glycyrrhizae is main flavour of a drug, and each flavour of a drug is collaborative each other, to reach the effect of " benefiting QI for activating blood circulation, detoxifcation mind calming ".Show its no overt toxicity reaction through animal acute toxicity experiment and clinical verification, and evident in efficacy, safety, expense is low, have no side effect.
The technological progress that the present invention obtains: with " benefiting QI for activating blood circulation, detoxifcation mind calming " is the treatment rule, utilizes the characteristic of Chinese medicinal components, through the science compatibility; Dilated cardiomyopathy, patients with heart failure not only there is the myocardium shrinkage function of improvement; Remove oxygen-derived free radicals, improve and the inhibition myocardial fibrosis cardiac muscle of protection hypoxic-ischemic and viral infection; Remove effects such as persistent viral infection, also have the effect of regulating immunologic function, improving Abwehrkraft des Koepers.The treatment dilated cardiomyopathy had significant curative effect.Show that through clinical practice the conventional cooperation of doctor trained in Western medicine myocardial viability granule is light to dilated cardiomyopathy, the moderate patients with heart failure all can obtain excellent curative, can obviously improve dilated cardiomyopathy patient's clinical symptoms, sign, and not have obvious toxic-side effects.
The present invention shows in stripped and whole animal pharmacodynamic experiment result:
(1) toxicology test:
Research project: maximum dosage-feeding test.Get 40 of mices (each 20 of male and female Mus), be divided into two groups.Each organizes the equal fasting of mice 12 hours, and then, administration group mice is irritated stomach with the myocardial viability granule Cmax of 2 gram crude drug/ml; Capacity is a 0.4ml/10 gram body weight (heap(ed) capacity); Be administered twice altogether in 1st, 5 hours at interval, dosage was 160 gram crude drug/kilograms; 313.7 times (70 kilograms of clinical adults, 36 gram crude drug/days of consumption) of clinical consumption are equivalent to be grown up.
Conclusion: through acute toxicity test; Can't measure the LD50 of its mouse stomach, the maximum dose of its mouse stomach administration is 160 gram crude drug/kilograms, 313.7 times of (70 kilograms of clinical adults of the clinical consumption that is equivalent to be grown up; 36 gram crude drug/days of consumption), explain that this poison of drug property is less.
(2) pharmacodynamics test:
Research project: to the influence of amycin cardiomyopathy rat; Influence to the high oxygen consumption hypoxia-bearing capability of mouse cardiac muscle.
Conclusion: Pharmacodynamic test of active extract proves: the myocardial viability drinking particle can improve the content that amycin causes myocardial damage rat blood serum and SOD of heart tissue level, reduces serum and myocardium MDA; The myocardial viability granule can significant prolongation time-to-live during the high oxygen consumption of mouse cardiac muscle, improve hypoxia-bearing capability.Result of study is that clinical application provides certain pharmacology foundation.
Through clinical statistics, be through the dilated cardiomyopathy patient clinical experiment summary situation of including in:
(the employed title in clinical of use below the medicine of treatment dilated cardiomyopathy of the present invention is " a myocardial viability granule ".）
1. experimental technique adopts random packet, blind single, control experiment method.
120 routine dilated cardiomyopathy patients adopt the random digit table method to be divided into 2 groups at random.Male's 53 examples in treatment group (myocardial viability groups of grains) 60 examples, women's 7 examples, 19～65 years old age.Male's 47 examples in matched group (matched group) 60 examples, women's 13 examples, 18～65 years old age.Selected dilated cardiomyopathy, heart failure diagnosis and the Chinese medical discrimination of meeting of case; Age more than or equal to 18 years old, smaller or equal to 65 years old, be the main object of study (having other organ function sexually transmitted disease (STD) change person to get rid of case) of medicine long-term observation with light, the moderate chronic heart failure patient of cardiac function II～III level (NYHA).
2. test method
This research adopts at random contrast method to observe.Concrete randomization group technology is to work out the random assortment card by the clinical research personnel according to random table, and the clinical research personnel press the grouping of random card regulation and carry out by the sequencing that qualified experimenter studies.Two groups of parallel controls are observed.
3. Therapeutic Method
Test group: (Great Wall, Shijiazhuang hospitals of traditional Chinese and western medicine developments, specification: every bag 15 gram contains crude drug amount 11.61g, lot number to oral myocardial viability granule: 080809,090726) each 1 bag of ante cibum sooner or later.Other gives conventional oxygen uptake, western medicines such as heart tonifying, diuresis, expansion blood vessel.
Matched group: give conventional oxygen uptake, western medicines (all same test group of method, medicine) such as heart tonifying, diuresis, expansion blood vessel.
Treatment time: be one month the course of treatment.
4. criterion of therapeutical effect is:
Curative effect of disease criterion was with reference to " new Chinese medicine clinical research guideline " in 2002
(1) produce effects heart failure basic controlling or cardiac function improve person more than 2 grades.
(2) effectively cardiac function improves 1 grade, but 2 grades of persons of less than.
(3) invalid cardiac function improves 1 grade of person of less than.
(4) worsening cardiac function worsens more than 1 grade or 1 grade.
Tcm syndrome curative effect determinate standard: with reference to " new Chinese medicine clinical research guideline " in 2002.
(1) the basic or complete obiteration of produce effects primary and secondary disease, treatment back syndrome integration is 0 or reduces >=70%.
(2) effectively treatment back syndrome integration reduces >=30%.
(3) the syndrome integration reduces less than 30% after the futile treatment.
(4) worsen treatment back syndrome integration more than or equal to the preceding integration of treatment.
Annotate: meter is calculated public formula ﹙ nimodipine method ﹚ and is: (integration before (integration before the treatment-treatment back integration) ÷ treatment) * 100%
5. statistical result:
5.1 curative effect index is observed:
The variation (
S) of myocardial viability groups of grains and treatment of control group left ventricular diastole end internal diameter
| Project | Group | n | Before the treatment | After the treatment | P | Difference before and after treating | P |
| LVd | The treatment group | 60 | 70.08±9.13 | 66.34±9.05 | 0.027 | 4.72±4.12 | 0.021 |
| （mm） | Matched group | 60 | 73.11±9.45 | 69.23±10.14 | 0.032 | 3.25±2.47 | ? |
Myocardial viability groups of grains and the fractional variation of treatment of control group left ventricular ejection (
S)
| Project | Group | n | Before the treatment | After the treatment | P | Difference before and after treating | P |
| EF | The treatment group | 60 | 25.7±10.32 | 34.6±10.39 | 0.000 | 9.19±5.82 | 0.027 |
| （%） | Matched group | 60 | 23.0±10.49 | 31.1±10.70 | 0.000 | 6.67±6.28 | ? |
The variation (
S) of ambition ratio before and after myocardial viability groups of grains and the treatment of control group
| Project | Group | n | Before the treatment | After the treatment | P | Difference before and after treating | P |
| The ambition ratio | The treatment group | 60 | 0.60±0.072 | 0.55±0.060 | 0.000 | 0.049±0.005 | 0.021 |
| ? | Matched group | 60 | 0.62±0.068 | 0.59±0.069 | 0.000 | 0.033±0.003 | ? |
5.2 the variation of traditional Chinese medical science cardinal symptom syndrome integration after myocardial viability groups of grains and the treatment of control group:
The variation of the cardiopalmus of tcm symptom integration (
S)
| Project | Group | The example number | Before the treatment | After the treatment | Z | P |
| Cardiopalmus | The treatment group | 60 | 2.37±0.52 | 1.27±0.45 | -6.903 | 0.00 |
| ? | Matched group | 60 | 2.28±0.58 | 1.42±0.53 | -7.076 | 0.00 |
| ? | Z | ? | -0.697 | -1.753 | ? | ? |
| ? | P | ? | 0.486 | 0.048 | ? | ? |
The variation of breathing hard of tcm symptom integration (
S)
| Project | Group | The example number | Before the treatment | After the treatment | Z | P |
| Breathe hard | The treatment group | 60 | 2.2±0.44 | 1.27±0.55 | -6.621 | 0.00 |
| ? | Matched group | 60 | 2.32±0.47 | 1.52±0.62 | -6.651 | 0.00 |
| ? | Z | ? | -1.359 | -2.272 | ? | ? |
| ? | P | ? | 0.164 | 0.021 | ? | ? |
The variation of the asthma of tcm symptom integration (
S)
| Project | Group | The example number | Before the treatment | After the treatment | Z | P |
| Asthma | The treatment group | 60 | 1.98±0.47 | 0.85±0.36 | -7.429 | 0.00 |
| ? | Matched group | 60 | 2.13±0.47 | 1.37±0.49 | -6.379 | 0.00 |
| ? | Z | ? | -1.732 | -5.7 | ? | ? |
| ? | P | ? | 0.083 | 0.000 | ? | ? |
The variation uncomfortable in chest of tcm symptom integration (
S)
| Project | Group | The example number | Before the treatment | After the treatment | Z | P |
| Uncomfortable in chest | The treatment group | 60 | 1.62±0.9 | 0.52±0.5 | -5.885 | 0.000 |
| ? | Matched group | 60 | 1.87±0.43 | 1.1±0.68 | -5.729 | 0.014 |
| ? | Z | ? | -2.823 | -4.670 | ? | ? |
| ? | P | ? | 0.055 | 0.000 | ? | ? |
The dysphoric variation of tcm symptom integration (
S)
| Project | Group | The example number | Before the treatment | After the treatment | Z | P |
| Dysphoria | The treatment group | 58 | 1.63±0.58 | 0.48±0.50 | -6.818 | 0.00 |
| ? | Matched group | 60 | 1.70±0.59 | 1.17±0.42 | -5.657 | 0.00 |
| ? | Z | ? | -0.154 | -6.571 | ? | ? |
| ? | P | ? | 0.815 | 0.000 | ? | ? |
The variation of the spontaneous perspiration of tcm symptom integration (
S)
| Project | Group | The example number | Before the treatment | After the treatment | Z | P |
| Spontaneous perspiration | The treatment group | 60 | 1.90±0.75 | ? 0.72±0.45 | -6.340 | 0.000 |
| ? | Matched group | 60 | 1.90±0.30 | 1.45±0.50 | -5.196 | 0.000 |
| ? | Z | ? | -0.265 | -6.691 | ? | ? |
| ? | P | ? | 0.21 | 0.000 | ? | ? |
The variation of the cough of tcm symptom integration (
S)
| Project | Group | The example number | Before the treatment | After the treatment | Z | P |
| Cough | The treatment group | 60 | 1.98±0.34 | ? 0.92±0.28 | -7.077 | 0.000 |
| ? | Matched group | 60 | 2.15±0.36 | 1.35±0.82 | -5.355 | 0.009 |
| ? | Z | ? | -2.509 | -4.099 | ? | ? |
| ? | P | ? | 0.052 | 0.000 | ? | ? |
Comprehensive therapeutic effect analysis after myocardial viability groups of grains and the treatment of control group (example, %)
| Group | n | Produce effects (%) | Effectively (%) | Invalid (%) | Total effective rate (%) |
| The treatment group | 60 | 2（3.3） | 56（93.3） | 2（3.3） | 96.6 |
| Matched group | 60 | 0（0） | 33（55） | 27（45） | 55 |
Cardiac function improves the curative effect index analysis after myocardial viability groups of grains and the treatment of control group
| Group | n | Produce effects (%) | Effectively (%) | Invalid (%) | Worsen (%) | Total effective rate (%) |
| The treatment group | 60 | 5（8.3） | 37（61.7） | 18（30） | 0（0） | 70 |
| Matched group | 60 | 3（5） | 27（45） | 27（48.3） | 3（1.7） | 50 |
After myocardial viability groups of grains and the treatment of control group to the influence of liver function (glutamate pyruvate transaminase ALT)
| Group | Before the treatment | ? | After the treatment | ? | Statistic | P |
| ? | Total routine number | Unusual number | Total routine number | Unusual number | χ 2=0.0085 | 0.93 |
| The treatment group | 60 | 10 | 56 | 3 | ? | ? |
| Matched group | 60 | 14 | 55 | 3 | ? | ? |
After myocardial viability groups of grains and the treatment of control group to the influence of renal function (creatinine SCr)
| Group | Before the treatment | ? | After the treatment | ? | Statistic | P |
| ? | Total routine number | Unusual number | Total routine number | Unusual number | χ 2=0.4514 | 0.50 |
| The treatment group | 60 | 10 | 59 | 4 | ? | ? |
| Matched group | 60 | 19 | 59 | 3 | ? | ? |
After myocardial viability groups of grains and the treatment of control group to the influence of electrolyte (blood potassium K)
| Group | Before the treatment | ? | After the treatment | ? | Statistic | P |
| ? | Total routine number | Unusual number | Total routine number | Unusual number | χ 2=0.3641 | 0.55 |
| The treatment group | 60 | 4 | 60 | 0 | ? | ? |
| Matched group | 60 | 6 | 60 | 3 | ? | ? |
Show through above-mentioned animal pharmacodynamic experiment and patient's clinical statistics result; The present invention has and improves myocardium shrinkage function, regulates immunologic function, improves Abwehrkraft des Koepers, removes oxygen-derived free radicals, improves myocardial fibrosis, the cardiac muscle of protection hypoxic-ischemic and viral infection, removes effect such as persistent viral infection; Can significantly improve the clinical symptoms of dilated cardiomyopathy, patients with heart failure, can be used safely in clinical.With matched group relatively, it is obvious to have curative effect, the total effective rate of treatment dilated cardiomyopathy heart failure is 96.6%, apparently higher than 55% total effective rate of matched group; The total effective rate 70% that cardiac function improves.Take for a long time through clinical and patient and to show; The heart that the dilated cardiomyopathy patient is enlarged obviously dwindles; The conventional cooperation of doctor trained in Western medicine myocardial viability granule is light to dilated cardiomyopathy, the moderate patients with heart failure can obtain excellent curative; Can obviously improve dilated cardiomyopathy patient's clinical symptoms, sign, and not have obvious toxic-side effects.Myocardial viability granule and Western medicine drug combination can be used as one of effective ways of treatment dilated cardiomyopathy.
The specific embodiment
For further specifying the present invention, be described further below in conjunction with specific embodiment:
Embodiment 1: take by weighing Radix Astragali 180g, Radix Salviae Miltiorrhizae 120g, Radix Paeoniae Rubra 60g, Cortex Moutan 60g, Radix Rehmanniae 120g, Carapax Trionycis 60g, Fructus Forsythiae 80g, Rhizoma Coptidis 24g, Radix Sophorae Flavescentis 60g, Radix Glycyrrhizae 40g respectively.
With the above-mentioned Chinese medicinal ingredients that takes by weighing, choosing is clean respectively, adds 7 times of water gagings and decocts secondary, and each 1.5 hours, collecting decoction filtered, and filtrating is concentrated into the clear paste that relative density is 1.25-1.30 (60 ℃ of heat is surveyed), and is subsequent use.
According to preparation process, with Icing Sugar, dextrin mix homogeneously, make binding agent system soft material with thick paste, 14 eye mesh screens are granulated, 60-65 ℃ of oven dry, 10 eye mesh screen granulate, the compound membrane bag of adorning every bag 15 gram gets final product.
Embodiment 2: take by weighing Radix Astragali 150g, Radix Salviae Miltiorrhizae 90g, Radix Paeoniae Rubra 80g, Cortex Moutan 80g, Radix Rehmanniae 90g, Carapax Trionycis 70g, Fructus Forsythiae 50g, Rhizoma Coptidis 30g, Radix Sophorae Flavescentis 80g, Radix Glycyrrhizae 50g respectively.
With the above-mentioned Chinese medicinal ingredients that takes by weighing, choosing is clean respectively, adds 7 times of water gagings and decocts secondary, and each 1.5 hours, collecting decoction filtered, and filtrating is concentrated into the clear paste that relative density is 1.25-1.30 (60 ℃ of heat is surveyed), and is subsequent use.
According to preparation process, with Icing Sugar, dextrin mix homogeneously, make binding agent system soft material with thick paste, 14 eye mesh screens are granulated, 60-65 ℃ of oven dry, 10 eye mesh screen granulate, the compound membrane bag of adorning every bag 15 gram gets final product.
Function of the present invention cures mainly: benefiting QI for activating blood circulation, detoxifcation mind calming.Be used for blood stasis due to qi deficiency, pyretic toxicity and disturb sensation of oppression over the chest with shortness of breath due to the heart, the cardiopalmus edema, vexed, dimly red tongue, yellow fur, diseases such as thready and rapid pulse or short, knot or generation.Heart failure is seen above-mentioned card marquis person due to the dilated cardiomyopathy, is auxiliary therapeutic agent.Specification: every bag of 15g.Packing: medicinal composite membrane dress, every bag of 15g, 20 bags of every packings.Usage and dosage: oral.One time 1 bag, 2 times on the one.The child reduces by half or follows the doctor's advice.
Claims (2)
1. pure Chinese medicinal preparation of treating dilated cardiomyopathy is characterized in that the crude drug by following mass ratio:
The Radix Astragali 150～200; Radix Salviae Miltiorrhizae 90～150; Radix Paeoniae Rubra 50～80; Cortex Moutan 50～80;
Radix Rehmanniae 90～120; Carapax Trionycis 50～80; Fructus Forsythiae 50～90; Rhizoma Coptidis 18～30;
Radix Sophorae Flavescentis 50～80; Radix Glycyrrhizae 40～50;
Through decoct, concentrate, mixing, granulation, packing promptly get this preparation.
2. a kind of pure Chinese medicinal preparation of treating dilated cardiomyopathy according to claim 1 is characterized in that said crude drug ratio of quality and the number of copies is:
The Radix Astragali 180; Radix Salviae Miltiorrhizae 120; Radix Paeoniae Rubra 60; Cortex Moutan 60; Radix Rehmanniae 120;
Carapax Trionycis 60; Fructus Forsythiae 80; Rhizoma Coptidis 24; Radix Sophorae Flavescentis 60; Radix Glycyrrhizae 40;
Through decoct, concentrate, mixing, granulation, packing promptly get this preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100085877A CN102048895B (en) | 2011-01-17 | 2011-01-17 | Pure traditional Chinese medicine preparation for treating dilated cardiomyopathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100085877A CN102048895B (en) | 2011-01-17 | 2011-01-17 | Pure traditional Chinese medicine preparation for treating dilated cardiomyopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102048895A CN102048895A (en) | 2011-05-11 |
| CN102048895B true CN102048895B (en) | 2012-08-22 |
Family
ID=43953912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100085877A Active CN102048895B (en) | 2011-01-17 | 2011-01-17 | Pure traditional Chinese medicine preparation for treating dilated cardiomyopathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102048895B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102258623B (en) * | 2010-05-27 | 2014-05-07 | 王伟 | Chinese medicine composition for treating coronary disease and cardiac insufficiency and preparation method thereof |
| CN102526631B (en) * | 2012-02-21 | 2013-08-14 | 葛祥成 | Traditional Chinese medicine preparation, tablet and capsule for curing dilated cardiomyopathy and preparation method |
| CN102824612B (en) * | 2012-09-20 | 2013-09-11 | 河南中医学院 | Traditional Chinese medicine for treating dilated cardiomyopathy |
| CN104352750A (en) * | 2014-09-29 | 2015-02-18 | 李中昕 | Traditional Chinese medicinal electuary for treating dilated cardiomyopathy and preparation method of granules of traditional Chinese medicinal electuary |
| CN104800589A (en) * | 2015-05-19 | 2015-07-29 | 青岛大学附属医院 | Traditional Chinese medicine for treating dilated cardiomyopathy and preparation method |
| CN104906343A (en) * | 2015-05-25 | 2015-09-16 | 济南正骐生物科技有限公司 | Traditional Chinese medicine for treating dilated cardiomyopathy and preparing method |
| CN105434589A (en) * | 2015-12-31 | 2016-03-30 | 王仁平 | Anti-fibrosis heart protecting decoction |
| CN109966461B (en) * | 2019-04-11 | 2021-08-10 | 中国中医科学院广安门医院 | Traditional Chinese medicine composition for treating dilated cardiomyopathy and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101069733A (en) * | 2006-05-11 | 2007-11-14 | 李石滚 | Medicine for treating viral myocarditis and cardiac muscle diseases |
| CN101322801A (en) * | 2007-06-15 | 2008-12-17 | 河北以岭医药研究院有限公司 | Use of Chinese medicinal composition in preparing medicament for treating dilated cardiomyopathy |
-
2011
- 2011-01-17 CN CN2011100085877A patent/CN102048895B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101069733A (en) * | 2006-05-11 | 2007-11-14 | 李石滚 | Medicine for treating viral myocarditis and cardiac muscle diseases |
| CN101322801A (en) * | 2007-06-15 | 2008-12-17 | 河北以岭医药研究院有限公司 | Use of Chinese medicinal composition in preparing medicament for treating dilated cardiomyopathy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102048895A (en) | 2011-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102048895B (en) | Pure traditional Chinese medicine preparation for treating dilated cardiomyopathy | |
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN104491052B (en) | Traditional Chinese medicine composition for treating rheumatic and rheumatoid arthritis and preparation method thereof | |
| CN102166278A (en) | Chinese medicinal composition for treating pediatric rheumatoid arthritis and preparation method thereof | |
| CN101502626B (en) | Medicament for treating influenza and preparation method thereof | |
| CN102847061B (en) | Traditional Chinese medicine preparation for treating pediatric viral myocarditis and preparation method thereof | |
| CN101306138B (en) | Chinese traditional injection preparation for treating chest stuffiness and pains and its preparation method | |
| CN104042713B (en) | A kind of Chinese medicine composition for the treatment of bronchial asthma | |
| CN103751325A (en) | Fengtongning traditional Chinese medicine preparation and its preparation method | |
| CN103191282B (en) | Traditional Chinese medicinal composition for treating fever in children as well as preparation method and application thereof | |
| CN105456818A (en) | Traditional Chinese medicine composition containing folium artemisiae argyi and being capable of treating insomnia and preparation method of traditional Chinese medicine composition | |
| CN104940691A (en) | Treatment medicine for novel bunyaviridae infection | |
| CN101554471B (en) | Traditional Chinese medicine preparation for treating myocardial infarction | |
| CN103610934B (en) | A kind of Chinese medicine for the treatment of pharyngitis | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN102133336B (en) | Traditional Chinese medicine composite, and preparation method and application thereof | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN104337898B (en) | A kind of Chinese medicine composition of the treatment gout containing Semen Pruni | |
| CN103721058A (en) | Traditional Chinese medicine preparation for preventing influenza viruses | |
| CN103182035B (en) | Traditional Chinese medicine composition used for treating chronic arrhythmia of elderly people and preparation method of traditional Chinese medicine composition | |
| CN102784307A (en) | Traditional Chinese medicine for treating phthisis and preparation method thereof | |
| CN102406753B (en) | Chinese medicinal composition for treating Bi syndrome | |
| CN101757423A (en) | Traditional Chinese medicine composition for treating myocarditis and preparation method thereof | |
| CN104825756A (en) | Traditional Chinese medicine composition for treating chronic renal failure | |
| CN104784567B (en) | A kind of pharmaceutical composition for the treatment of urinary system infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |